Attenuation of fear-like response by escitalopram treatment after electrical stimulation of the midbrain dorsolateral periaqueductal gray

Exp Neurol. 2010 Dec;226(2):293-300. doi: 10.1016/j.expneurol.2010.08.035. Epub 2010 Sep 15.

Abstract

Electrical stimulation of the dorsolateral periaqueductal gray (dlPAG) has frequently been shown to induce escape and freezing/decreased locomotion responses which mimic panic- and fear-like behaviour. In the present study we tested whether such spontaneous fear-like behaviour could be observed in an open-field test 12 h after dlPAG stimulation. Further, we tested whether this fear-like behaviour could be attenuated by acute or chronic administration of buspirone and escitalopram. Our data demonstrate for the first time that animals showed fear-like behaviour 12 h after dlPAG stimulation, which may possibly reflect panic disorder with anticipatory anxiety/agoraphobic symptoms. Acute and chronic escitalopram, but not buspirone, treatment attenuated the fear-related behaviour. Besides, our data also showed that the stimulation intensities to evoke an escape reaction, a panicogenic response, were significantly higher after chronic buspirone and escitalopram treatment. These results suggest that the fear-like response, which was observed 12 h after dlPAG stimulation, could be considered as a relevant animal model for panic disorder with anticipatory anxiety/agoraphobic symptoms.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Anxiety Agents / pharmacology
  • Antidepressive Agents, Second-Generation / pharmacology*
  • Buspirone / pharmacology
  • Citalopram / pharmacology*
  • Deep Brain Stimulation*
  • Escape Reaction / drug effects
  • Escape Reaction / physiology
  • Exploratory Behavior / drug effects
  • Exploratory Behavior / physiology
  • Fear / drug effects*
  • Fear / psychology
  • Locomotion / drug effects
  • Male
  • Periaqueductal Gray / physiology*
  • Random Allocation
  • Rats
  • Rats, Wistar

Substances

  • Anti-Anxiety Agents
  • Antidepressive Agents, Second-Generation
  • Citalopram
  • Buspirone